Ami

(redirected from Acute myocardial infarction)
Also found in: Dictionary, Thesaurus, Medical, Financial, Acronyms, Encyclopedia, Wikipedia.

AMI. A friend; or, as it is written in old works, amy. Vide Prochein amy.

References in periodicals archive ?
Acute myocardial infarction in young and very old Chinese adults: clinical characteristics and therapeutic implications.
Recent preliminary data from the MAGIC-trial indicated that G-CSF treatment in patients with acute myocardial infarction could aggravate in-stent restenosis rate (19).
Rupture of the left ventricular free wall during acute myocardial infarction: Analysis of 138 necropsy patients and comparison with 5 necropsy patients with acute myocardial infarction without rupture.
The clinical significance of bundle branch block complicating acute myocardial infarction.
The study of 496 acute myocardial infarction patients showed that the combination of enoxaparin and streptokinase restored normal coronary blood flow in the blocked artery by a relative increase of 22% vs.
Stentys offers a new generation of stents, which are specifically designed for the treatment of Acute Myocardial Infarction (AMI).
Objectives of the Phase I Myocardial Infarction (MI) trial were to determine the safety, pharmacokinetics and immunogenicity of TP10 with first-time, acute myocardial infarction patients, ages 18 - 75.
Staten Island University Hospital, was rated in the top five percent nationally and in the top tiers of hospitals as it achieves a second decile ranking based on second-year overall quality score in the clinical focus areas of acute myocardial infarction (AMI), coronary artery bypass graft (CABG) and heart failure.
Smalling's preclinical model of heart attacks, also known as acute myocardial infarction, the main artery carrying blood to the heart was blocked by formation of a clot, similar to the way heart attacks occur in people.
Improvements in quality of care saved 1,284 acute myocardial infarction (heart attack) patients, according to an analysis of mortality rates at hospitals participating in the HQID project.
NASDAQ: ARAM) today announced that they have initiated Phase 1 clinical trials with GP-1-668, a second-generation adenosine regulating agent (ARA) for potential use in unstable angina, acute myocardial infarction and/or the prevention of adverse cardiovascular outcomes associated with major non-cardiac surgery.

Full browser ?